Key Takeaways
- Merger integration hits JB top line, but base business accelerates: JB revenues were flat YoY at ₹1,086 crores as international disruption masked 7% India branded growth, while Torrent’s base business grew 18% led by India at 20% and Brazil at 38%.
- Cost synergies are running ahead of plan: JB EBITDA margins improved sequentially despite the transient sales impact, and management now expects most of the ~₹450 crores in cost synergies to be realized by FY28, a year ahead of the original three-year timeline.
- R&D spend is stepping up for a U.S. filing catch-up: R&D rose to 4.2% of revenue, a 0.7% QoQ increase, as the company accelerates U.S. filings from very low single digits to high single digits for some years to recover lost ground from prior operational issues; this elevated spend is expected to persist for 2–3 years.
- India IPM tailwind is real but unexplained: H1 IPM growth at 12% is 2–3% above recent years, and management cannot pinpoint the cause; both branded and trade generic segments appear to be growing, and the trend is expected to sustain for the rest of this year.
- What to watch next quarter: Whether JB International disruption truly proves transient as deliveries resume, the pace of sequential JB EBITDA margin improvement, and any stabilization in the struggling German business.
Merger Integration: The JB Story
- India integration executed smoothly: Divisional and field force mergers were completed as planned, and despite the integration activity, JB’s India branded business delivered 10% H1 growth with H2 expected perhaps higher than that.
- International disruption was back-office, not demand-driven: A ~7% decline in JB International revenues stemmed from plant network optimization, software and accounting integration, and a U.S. product recall due to quality issues, not front-office customer losses; management calls the impact transient and one-time in nature.
- Recovery path is staggered: India recovery is expected to be gradual quarter-on-quarter, while International recovery may take slightly longer; total JB business growth is guided to recover to double-digit in H2.
- Field force merger savings are already visible: The sequential improvement in JB EBITDA margin was largely driven by field force merger savings realized from India divisional consolidation, with a small part of it from procurement savings.
- Profitability convergence is the endgame: Once the improvement cycle is complete, JB’s India business profitability is expected to be very similar to Torrent’s India business.
Sanjay Gupta: "We're talking about back-office issues. We are not talking about front office customer-facing issues."
Base Business Momentum
- India base business is firing on all cylinders: 20% growth was driven by an overall increase in IPM growth, strong new launch performance, and volume growth acceleration from field force expansion; the combined Torrent plus JB India field force now stands at 9,100.
- Curatio is scaling rapidly: The acquired OTC business grew 34% in Q2 and H1, driven by advertising spends and field force expansion, and its contribution has risen from 4–5% at acquisition to 7–8% of base India business; management expects the high growth trajectory to continue for at least a couple of years.
- Brazil is a standout: 21% constant currency growth (26% per IQVIA vs. a 5.7% market) was aided by strong performance of the top brand, recent launches, and strong growth in the generics division; growth is split roughly one-third each from price, volume, and new launches.
- U.S. growth is launch-dependent: 13% constant currency growth came entirely from new product launches where target market share was achieved or exceeded; the base business is flat, with price erosion and volume growth offsetting each other on mature products.
- Germany remains a drag: A 13% constant currency decline was driven by loss of high-value tenders and disruption at third-party suppliers, compounded by government-mandated price decreases affecting the non-retail business; best-case outlook is a slight decline in coming quarters with eventual stability after three or four quarters.
Sanjay Gupta: "So I really cannot give guidance today. Best case, I would say, slight decline in the coming quarters, and eventually some stability after maybe three or four quarters."
Cost Synergies & Margin Trajectory
- Synergy timeline has been pulled forward: Management now believes most of the ~₹450 crores in cost synergies could come through by FY28, achievable in two years instead of the original three; the company is tracking ahead of its initial plan.
- Revenue synergies will take longer: India revenue synergies from cross-selling JB brands into new territories should start gradually coming through over the next 6–12 months, with reasonable top-line improvement expected next year; International revenue synergies are a 2–3 year journey because product filing takes longer in most markets.
- Combined EBITDA margin should inch up: Q2 combined EBITDA margin was 33.5%; management expects a gradual increase with H2 FY27 higher than 33.5%, and JB EBITDA margins should continue improving quarter-on-quarter for the next two to three quarters.
- R&D spend is the margin headwind to watch: R&D rose to 4.2% of revenue and is expected to stay in the 4–4.5% range even next year as the company accelerates U.S. filings; this is described as temporary spend for 2–3 years to recover lost time from operational issues in prior years.
Sudhir Menon: "And having said that, we believe most of it could come through by the next year."
Product & Market-Specific Bets
- Generic semaglutide is a material India opportunity: The market is on track to reach ~₹800 crores in its first year, with very high growth expected in the first couple of years followed by stabilization in the third or fourth year; management sees a ₹2,000–2,500 crores market in 3–5 years as "not out of range."
- Semaglutide injectable supply is restored: A supply disruption kept Torrent out of the market for nearly two months, causing minor market share loss; a new manufacturing partner has been onboarded and market supplies were fully restored by September, with confidence that a large part of the share loss will be recovered.
- Brazil GLP-1 launch is on the horizon: One true generic has already been launched by a local large player three months ago, accelerating market growth; Torrent optimistically expects to launch its own GLP-1 in the next six to nine months.
- U.S. filing acceleration is underway: Four products have been filed year-to-date, with 4–5 more expected before fiscal year-end, totaling 9–10 for the year, higher than each of several previous years; this gives management positive optimism for future growth.
- OTC strategy is brand-extension led: The company is launching multiple brand extensions to create a sizable base in 2–3 years and is keeping a lookout for acquisitions to bolt on to the OTC platform; no completely new OTC product launches have occurred in the last 6–8 months.
India Market & Competitive Dynamics
- IPM growth is running hot, and the cause is unclear: H1 IPM growth at 12% is 2–3% above preceding years; management cannot pinpoint the exact cause of the delta, noting that trade generic business has not slowed materially and both branded and trade generic segments appear to be growing.
- The trend looks durable for now: IPM growth is likely to sustain for the rest of this year; next year may drop 1–2% but minimum 10% should continue at least for the next financial year, with below 10% "not looking likely at this stage."
- Generic sema pricing is expected to be stable or gradually increase: Management sees no real price erosion in the India semaglutide market; the objective is to expand the market and defend share, with prices expected to be stable or gradually increase over the next couple of years.
- Field force expansion is on the table: The combined MR headcount of 9,100 will be maintained through FY27 end; potential expansion in the base business by ~500 MRs next year, possibly reaching 9,500 to 9,600, with a review in a couple of months.
Aman Mehta: " It's very difficult to pinpoint still. ... what is causing the higher, say, 2%, 3% market delta is still difficult to pinpoint exactly."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| JB total business growth recovery | Double-digit growth in H2 FY27 | H2 FY27 |
| JB India branded growth acceleration | H2 growth higher than H1's 10% | H2 FY27 |
| Cost synergy realization | Most of ~₹450 crores achieved | By FY28 (next year) |
| Combined EBITDA margin | Gradual increase; H2 FY27 higher than 33.5% | H2 FY27 |
| JB EBITDA margin | Gradual quarter-on-quarter improvement | Next 2–3 quarters |
| R&D spend range | Not to exceed 4–4.5% of revenue | Current year and following year |
| U.S. filings | 4–5 more products, totaling 9–10 for FY27 | By fiscal year-end |
| India MR headcount | Maintain at 9,100; potential expansion to 9,500–9,600 | Through FY27 end; review in a couple of months |
| Brazil GLP-1 launch | Optimistically expect to launch | Next 6–9 months |
| Germany stabilization | Eventual stability after slight decline in coming quarters | After 3–4 quarters |
| FY28/29 guidance | Will provide guidance | Q1 next year (FY28) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹4,979 cr, up 51% YoY |
| Operating EBITDA | ₹1,666 cr, up 54% YoY |
| Operating EBITDA margin | 33.5%, vs 33.8% in Q1 FY27; R&D spend increased 0.7 ppt QoQ to 4.2% of revenue |
| R&D spend | 4.2% of revenue, up from 3.5% in Q1 FY27; expected range 4% to 4.5% going forward |
| Net debt to EBITDA | 1.8x |
| Torrent base business revenue growth | 18% YoY |
| Torrent India base business revenue | ₹2,181 cr, growth of 20% YoY vs IPM growth of 12% |
| JB business underlying revenue | ₹1,086 cr, largely flat YoY |
| JB India branded business growth | 7% YoY; H1 FY27 growth at 10% |
| JB International business growth | down 7% YoY |
| Curatio business growth | 34% YoY in Q2 and H1 FY27; now 7% to 8% of base India business vs 4% to 5% at acquisition |
| Combined India field force strength | 9,100 (Torrent plus JB) at end of Q2; potential expansion to 9,500–9,600 next year |
| Semaglutide India franchise market share | 32% for oral and injectable combined (per PharmaTrac); over 90% share within generic players for oral segment |
| Brazil constant currency revenue | BRL23.6 cr, up 21% YoY; IQVIA growth at 26% vs market growth of 5.7% |
| U.S. constant currency revenue | $44 million, up 13% YoY |
| Germany constant currency revenue | EUR2.6 cr, down 13% YoY |
| Brazil pipeline | 53 molecules under ANVISA review, approvals expected in next two years |
| U.S. filings year-to-date | 4 products filed, 4 to 5 more expected before fiscal year-end, totaling 9–10 products |
| Generic semaglutide India estimated first-year market size | ~₹800 cr, on track to reach that level |
| Ophthalmology deal second tranche payment | ~₹950–960 cr, due December of this year |
| Cost synergy estimate | ~₹450 cr, with roughly half already reflected in margins; expected to be fully realized in two years instead of three |
| H2 FY27 JB overall growth guidance | double-digit; India higher than double-digit, International recovery gradual |
| H2 FY27 consolidated EBITDA margin outlook | higher than 33.5%, gradual improvement expected |
| Brazil growth outlook | at least superior to 10%, closer to 15% in coming years |
| ROW markets growth (ex-Brazil branded) | 6% to 9% conservatively (not JB, total) |
| IPM growth outlook | 12% in H1 FY27; expected to sustain for rest of year, next year may drop 1–2% but minimum 10% likely |